Salvage Chemotherapy with Cisplatin, Ifosfamide, and Paclitaxel in Aggressive Variant of Metastatic Castration-Resistant Prostate Cancer

Significant progress has been achieved in the treatment of metastatic castration-resistant prostate cancer (mCRPC). However, results in patients with aggressive variant prostate cancer (AVPC) have been disappointing. Here, we report retrospectively collected data from intensively pretreated AVPC pat...

Descripción completa

Detalles Bibliográficos
Autores principales: von Amsberg, Gunhild, Zilles, Mirjam, Mansour, Wael, Gild, Philipp, Alsdorf, Winfried, Kaune, Moritz, Böckelmann, Lukas, Hauschild, Jessica, Krisp, Christoph, Rohlfing, Tina, Saygi, Ceren, Alawi, Malik, Zielinski, Alexandra, Langebrake, Claudia, Oh-Hohenhorst, Su Jung, Perner, Sven, Tilki, Derya, Schlüter, Hartmut, Graefen, Markus, Dyshlovoy, Sergey A., Bokemeyer, Carsten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9738104/
https://www.ncbi.nlm.nih.gov/pubmed/36499277
http://dx.doi.org/10.3390/ijms232314948

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9738104/
https://www.ncbi.nlm.nih.gov/pubmed/36499277
http://dx.doi.org/10.3390/ijms232314948

Ejemplares similares